Edwards Lifesciences Stock at $78: Here’s the Analysts’ Bull Case Scenario

Edwards Lifesciences (EW) shares recently rose 4% to $78.92 after a stronger-than-expected Q4 earnings report, with revenue of $1.57 billion driven by strong TAVR and TMTT sales. The company’s future looks promising with raised EPS guidance, new product launches, and a shifting market perception from a single-product company to a multi-therapy structural heart platform. Analysts have a mean price target of $96.50, implying a 22% upside, and a DCF model suggests a 70.4% total return by 2030, indicating the stock is potentially undervalued.